Topcon 3D OCT OS
- Early Dx of SD may help development of early interventions and benefit patients the most.
- Genetic confirmation, registration of patient into central registry, and publication of natural history data may help locate patients for trials and improve patient counseling.
- Oral treatment such as ALK-001 from Alkeus Pharmaceuticals may prevent formation of toxic vit A dimers in the retina.7 Earliest drug activity may be monitored by images.
- Patients with SD should not be on high levels of vit A (preformed vitamin A). Vegetable and fruit vitamin A are okay.
- In SD, defective ABCA4 gene leads to improper shuttling of vit A out of the photoreceptors, and in formation of toxic vitamin A dimers.